Amicus Therapeutics, Inc. (FOLD)

NASDAQ: FOLD · IEX Real-Time Price · USD
7.49
-0.25 (-3.23%)
May 18, 2022 11:07 AM EDT - Market open
Market Cap2.10B
Revenue (ttm)317.83M
Net Income (ttm)-270.06M
Shares Out280.16M
EPS (ttm)-0.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume653,087
Open7.46
Previous Close7.74
Day's Range7.13 - 7.63
52-Week Range5.91 - 12.63
Beta1.32
AnalystsBuy
Price Target14.62 (+95.2%)
Earnings DateMay 9, 2022

About FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate t...

IndustryBiotechnology
IPO DateMay 31, 2007
CEOJohn Crowley
Employees496
Stock ExchangeNASDAQ
Ticker SymbolFOLD
Full Company Profile

Financial Performance

In 2021, FOLD's revenue was $305.51 million, an increase of 17.11% compared to the previous year's $260.89 million. Losses were -$250.46 million, -9.53% less than in 2020.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for FOLD stock is "Buy." The 12-month stock price forecast is 14.62, which is an increase of 95.19% from the latest price.

Price Target
$14.62
(95.19% upside)
Analyst Consensus: Buy
Stock Forecasts

News

7 Biotech Stocks With Key Catalysts for May

The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on InvestorP...

1 week ago - InvestorPlace

Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA

PHILADELPHIA, May 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by 90 days for the Biolo...

1 week ago - GlobeNewsWire

Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates

Amicus Therapeutics (FOLD) posts a wider-than-expected loss for the first quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.

1 week ago - Zacks Investment Research

Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25% and 2.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

CORRECTING AND REPLACING -- Amicus Therapeutics Announces First Quarter 2022 Financial Results

1Q22 Galafold ® Revenue Growth of 18.5% to $78.7M

1 week ago - GlobeNewsWire

Amicus Therapeutics Announces First Quarter 2022 Financial Results

1Q22 Galafold ® Revenue Growth of 18.5% to $78.7M

1 week ago - GlobeNewsWire

Why Amicus (FOLD) Might Surprise This Earnings Season

Amicus (FOLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 week ago - Zacks Investment Research

Bears are Losing Control Over Amicus Therapeutics (FOLD), Here's Why It's a 'Buy' Now

Amicus Therapeutics (FOLD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement am...

1 week ago - Zacks Investment Research

Amicus Therapeutics to Present at the Bank of America 2022 Healthcare Conference

PHILADELPHIA, May 04, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2022 Healthcare Conference in...

2 weeks ago - GlobeNewsWire

Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

Amicus Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

PHILADELPHIA, April 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 9, 2022 at 8:30 a.m...

3 weeks ago - GlobeNewsWire

Amicus Announces Issuance of New U.S. Composition of Matter Patent for Galafold® (migalastat), Strengthening Patent P...

Galafold U.S. Intellectual Property Protection Now Includes 35 Issued Patents, 18 of which expire in 2038 Galafold U.S. Intellectual Property Protection Now Includes 35 Issued Patents, 18 of which expir...

4 weeks ago - GlobeNewsWire

Amicus Therapeutics Among Small Biotechs Cutting Back

Amicus Therapeutics Inc. ( FOLD , Financial) is the poster child for the malaise affecting small biotechs, especially those working on gene and cell therapy. Owners of the stock are hoping the company's...

1 month ago - GuruFocus

Amicus Shares Encouraging Long-Term Data Of AT-GAA Study In Pompe Disease

Amicus Therapeutics Inc (NASDAQ: FOLD) has announced additional results from a Phase 1/2 clinical study of AT-GAA in adult patients with Pompe disease. Study participants treated with AT-GAA for up to 3...

2 months ago - Benzinga

Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA...

Meaningful and Durable Responses in Key Endpoints of Six-Minute Walk and Forced Vital Capacity

2 months ago - GlobeNewsWire

Amicus Therapeutics Announces Presentation and Posters at the 2022 MDA Clinical & Scientific Conference

PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will be ...

2 months ago - GlobeNewsWire

Amicus Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Cowen 42n...

2 months ago - GlobeNewsWire

Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -107.14% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates

Galafold ®  Revenue Growth of 17% YoY to $306M in 2021

2 months ago - GlobeNewsWire

Gene Therapy Player Amicus Therapeutics Terminates SPAC Merger, Shares Fall

Amicus Therapeutics Inc (NASDAQ: FOLD) has terminated its plans to spin off its gene therapy assets, citing 'existing market conditions.' With "market conditions" sinking the planned merger with ARYA Sc...

2 months ago - Benzinga

Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Amicus Therapeutics to Announce Full-Year 2021 Financial Results on February 24, 2022

PHILADELPHIA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 24, 2022 at 8...

3 months ago - GlobeNewsWire

Amicus Therapeutics Announces Presentations and Posters at the 18th Annual WORLDSymposium™ 2022

PHILADELPHIA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare di...

3 months ago - GlobeNewsWire

Amicus Therapeutics (FOLD) Stock Jumps 6.4%: Will It Continue to Soar?

Amicus Therapeutics (FOLD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near...

4 months ago - Zacks Investment Research

Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance

Full-Year 2021 Galafold ® Revenue of ~$306M, Representing 17% YoY Growth

4 months ago - GlobeNewsWire